Transplant-free survival in acute liver failure patients receiving Molecular Adsorbent Recirculating System (MARS)®, plasma exchange or no liver support. A real-life 21-year retrospective cohort study in a referral center
An erratum to this article was published (Ann Intensive Care, 10 Oct 2025 ↗)
Authors' conclusion
MARS therapy improved TFS only in patients who received ≥ 3 sessions. Compared with controls, HVPE-treated patients experienced improved transplant-free and overall survival.
Study context
- Population
- Patients admitted to ICU with acute liver failure (ALF) fulfilling LTx criteria, referral centre, 2000 to 2021A 68, B 70, C 61
- Participants
- 199 patients
- Exposure
- MARS vs no MARS; High-volume plasma exchange (HVPE) vs control
- HVPEn = 45
- Controln = 126reference
- Outcome
- Transplant-free survival (TFS)
- Follow-up
- Day 21
Methodological detailssingle referral centre, 21-year period
- Single referral centre
- 21-year period
Main finding
TFS
Adjusted hazard ratio
0.54
CI 0.32–0.93
P = 0.0257
By group
HVPE vs Control
adjusted HR 0.54 (CI 0.32–0.93); P = 0.0257
As reported in the abstract
Observational data: associations, not effects.
Further findings
OS · Day 28
P = 0.03
Original publication
Transplant-free survival in acute liver failure patients receiving MARS®, plasma exchange or no liver support. A real-life 21-year retrospective cohort study in a referral center. Ann Intensive Care. Published 26 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →